VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...

Please provide your email address to receive an email when new articles are posted on . Previously granted FDA breakthrough device designation in January 2020, ColoSense is the “first noninvasive ...

CINCINNATI, June 20, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today two new ...

The NCCN Guidelines are comprehensive, evidence-based recommendations to support the prevention, diagnosis, and treatment of more than 97% of cancers affecting patients in the United States. They are ...

The US Food and Drug Administration (FDA) has approved ColoSense (Geneoscopy, Inc), a multitarget stool RNA (mt-sRNA) test for colorectal cancer (CRC) screening in adults aged 45 or older who are at ...

VANCOUVER, BC — Two multitarget stool tests in development compare favorably for colorectal cancer (CRC) screening in average-risk people, suggest two new studies. In a blinded, prospective, ...

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, announced the publication of a ...

Study aims to enhance colorectal cancer prevention by identifying polyp molecular signals, offering improved sensitivity over at-home DNA tests, which have limited ability to detect precancerous ...

A stool test is a diagnostic procedure that involves analyzing fecal matter, or poop, to check for signs of infection, inflammation, or disease. The specific analysis depends on a person’s symptoms ...

A University of Liverpool study has used advanced genetic and genomic techniques to offer a major step forward in understanding and diagnosing infectious intestinal diseases. The research is published ...